These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16161148)

  • 1. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report.
    Gambarin M; Antonini A; Moretto G; Bovi P; Romito S; Fiaschi A; Tinazzi M
    Mov Disord; 2006 Feb; 21(2):270-3. PubMed ID: 16161148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: A case report.
    Harada K
    Mov Disord; 2006 Dec; 21(12):2264; author reply 2264-5. PubMed ID: 17078069
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychiatric complications of L-dopa: physiopathology and treatment].
    Castro-García A
    Rev Neurol; 1997 Aug; 25 Suppl 2():S157-62. PubMed ID: 9280683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 7. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
    Rajput A; Kishore A; Snow B; Bolton CF; Rajput AH
    Mov Disord; 1997 May; 12(3):453-6. PubMed ID: 9159748
    [No Abstract]   [Full Text] [Related]  

  • 11. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 17. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
    Solla P; Cannas A; Congia S; Floris G; Aste R; Tacconi P; Marrosu MG
    J Neurol Sci; 2008 Dec; 275(1-2):154-6. PubMed ID: 18814889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical myoclonus in levodopa-responsive parkinsonism.
    Caviness JN; Adler CH; Newman S; Caselli RJ; Muenter MD
    Mov Disord; 1998 May; 13(3):540-4. PubMed ID: 9613750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
    Brodsky MA; Hogarth P; Nutt JG
    Mov Disord; 2006 Sep; 21(9):1487-90. PubMed ID: 16721730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.